Published in Steroids on January 04, 2007
Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem (2008) 1.26
The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol (2011) 1.19
Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol Cell Endocrinol (2009) 0.98
Progesterone receptor isoform functions in normal breast development and breast cancer. Crit Rev Eukaryot Gene Expr (2008) 0.97
Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer (2009) 0.94
Post-translational modifications of the progesterone receptors. J Steroid Biochem Mol Biol (2013) 0.88
Role of phosphorylation in progesterone receptor signaling and specificity. Mol Cell Endocrinol (2011) 0.88
Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation. Steroids (2008) 0.87
Cell-cycle regulation of NOTCH signaling during C. elegans vulval development. Mol Syst Biol (2012) 0.86
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Mol Endocrinol (2014) 0.84
The transcriptional co-activator PCAF regulates cdk2 activity. Nucleic Acids Res (2009) 0.84
Histone deacetylase 3 regulates cyclin A stability. J Biol Chem (2013) 0.80
The requirement for p42/p44 MAPK activity in progesterone receptor-mediated gene regulation is target gene-specific. Steroids (2013) 0.80
Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line. PLoS One (2012) 0.80
Resistance to inhibitors of cholinesterase (Ric)-8A and Gαi contribute to cytokinesis abscission by controlling vacuolar protein-sorting (Vps)34 activity. PLoS One (2014) 0.79
Cyclin is degraded by the ubiquitin pathway. Nature (1991) 17.93
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol (1997) 9.87
Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J (1990) 5.05
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet (2003) 4.74
Nuclear hormone receptors and gene expression. Physiol Rev (2001) 4.56
Cdk2 knockout mice are viable. Curr Biol (2003) 3.92
Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A (2003) 3.30
Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem (2001) 3.07
Mutagenic analysis of the destruction signal of mitotic cyclins and structural characterization of ubiquitinated intermediates. Mol Biol Cell (1996) 2.99
Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell (2004) 2.95
Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J (2003) 2.89
Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol (1993) 2.89
Physiological action of progesterone in target tissues. Endocr Rev (1997) 2.73
Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A (2000) 2.69
Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science (2000) 2.57
Cyclin A in cell cycle control and cancer. Cell Mol Life Sci (2002) 2.49
Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat Genet (1997) 2.01
Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol (1997) 1.88
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res (2003) 1.88
Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem (1998) 1.83
Steroid hormone receptors and their regulation by phosphorylation. Biochem J (1996) 1.75
Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol (2001) 1.70
A roller coaster ride with the mitotic cyclins. Semin Cell Dev Biol (2005) 1.66
8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol (2000) 1.64
Ligand-independent activation of steroid hormone receptors. J Mol Med (Berl) (1998) 1.63
Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol (1997) 1.62
Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem (2000) 1.58
New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res (1994) 1.55
Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem (1997) 1.50
Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem (1999) 1.48
A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol (1994) 1.48
Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol (2005) 1.41
Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol (2004) 1.40
Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol (2000) 1.39
Small-molecule cyclin-dependent kinase modulators. Oncogene (2003) 1.36
Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids (2003) 1.34
Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr Rev (2005) 1.32
In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology (1983) 1.31
Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol (2003) 1.31
Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem (1993) 1.27
Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol (2005) 1.25
Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol (1997) 1.22
Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol (1998) 1.20
A limiting factor mediates the differential activation of promoters by the human progesterone receptor isoforms. J Biol Chem (1992) 1.19
Histone H1 phosphorylation by Cdk2 selectively modulates mouse mammary tumor virus transcription through chromatin remodeling. Mol Cell Biol (2001) 1.17
Role of acidic and phosphorylated residues in gene activation by the glucocorticoid receptor. J Biol Chem (1995) 1.16
Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors. J Biol Chem (1996) 1.14
Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol (2003) 1.14
Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem (2000) 1.13
Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol Endocrinol (2003) 1.12
The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J Steroid Biochem Mol Biol (1994) 1.12
MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol (2003) 1.11
The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci U S A (1993) 1.08
Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. Endocrinology (1988) 1.06
Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids (2005) 1.04
Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol (1995) 1.04
Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc Natl Acad Sci U S A (1992) 1.03
Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci U S A (1996) 1.02
Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci U S A (1997) 1.02
Receptor mechanisms of rapid extranuclear signalling initiated by steroid hormones. Essays Biochem (2004) 1.00
Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors. Mol Endocrinol (1992) 0.99
Progesterone receptor (hPR) upregulates the fibronectin promoter activity in human decidual fibroblasts. DNA Cell Biol (2003) 0.99
Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J Biol Chem (1994) 0.97
Phosphorylation and progesterone receptor function. J Steroid Biochem Mol Biol (1995) 0.97
Site-directed mutagenesis of the phosphorylation sites in the mouse glucocorticoid receptor. J Biol Chem (1993) 0.94
Ligand activated hPR modulates the glycodelin promoter activity through the Sp1 sites in human endometrial adenocarcinoma cells. Mol Cell Endocrinol (2001) 0.88
Progesterone receptor activates its promoter activity in human endometrial stromal cells. Mol Cell Endocrinol (2002) 0.88
Stoichiometry and site-specific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system. J Biol Chem (1996) 0.87
Steadying the boat: integrating mechanisms of membrane and nuclear-steroid-receptor signalling. EMBO Rep (2005) 0.86
TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol (2006) 0.86
Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. Breast Cancer Res Treat (1993) 0.85
Differential regulation of human progesterone receptor A and B form-mediated trans-activation by phosphorylation. Endocrinology (1993) 0.81
Transcriptional activation by the oestrogen receptor alpha is modulated through inhibition of cyclin-dependent kinases. Oncogene (2002) 0.81
Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res (2005) 2.14
Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res (2006) 1.90
Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem (2006) 1.85
International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev (2006) 1.60
Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol (2003) 1.51
Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol (2005) 1.41
Repressors of androgen and progesterone receptor action. J Biol Chem (2003) 1.35
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem (2006) 1.31
Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther (2013) 1.28
Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol (2005) 1.25
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem (2009) 1.20
Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. Biofactors (2009) 1.13
Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol (2008) 1.12
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate (2005) 1.06
Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos (2011) 1.04
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol (2013) 1.03
Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol (2008) 1.03
A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab (2004) 1.03
Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res (2013) 1.03
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol (2012) 1.02
Coactivator selective regulation of androgen receptor activity. Steroids (2009) 1.02
Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J Biol Chem (2010) 1.01
p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology (2003) 1.00
Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids (2013) 0.99
Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell (2013) 0.99
1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology (2009) 0.99
Vitamin D and prostate cancer. Exp Biol Med (Maywood) (2004) 0.99
Vitamin D and prostate cancer. J Androl (2002) 0.97
Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s). J Biol Chem (2003) 0.97
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res (2006) 0.97
The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem (2004) 0.96
Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res (2009) 0.94
Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. Cancer Res (2010) 0.94
c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol (2005) 0.93
Drug metabolism and pharmacokinetics of 4-substituted methoxybenzoyl-aryl-thiazoles. Drug Metab Dispos (2010) 0.92
Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res (2013) 0.92
Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology (2010) 0.91
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res (2004) 0.91
Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate (2005) 0.91
Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem (2005) 0.91
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat (2014) 0.90
Novel phosphorylation target in the serum response factor MADS box regulates alpha-actin transcription. Biochemistry (2003) 0.90
Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J (2006) 0.90
EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther (2009) 0.90
Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol (2012) 0.89
1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology (2010) 0.88
Constitutively active FOXO1a and a DNA-binding domain mutant exhibit distinct co-regulatory functions to enhance progesterone receptor A activity. J Mol Endocrinol (2007) 0.88
Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids (2005) 0.87
Identification of a transferable two-amino-acid motif (GT) present in the C-terminal tail of the human lutropin receptor that redirects internalized G protein-coupled receptors from a degradation to a recycling pathway. Mol Endocrinol (2002) 0.87
Phosphorylation: a fundamental regulator of steroid receptor action. Trends Endocrinol Metab (2013) 0.86
Regulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus. Int J Biochem Cell Biol (2011) 0.85
Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. Mol Endocrinol (2009) 0.85
PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3). Steroids (2007) 0.84
Parametric investigation of nonlinear fluctuations in a dc glow discharge plasma. Chaos (2007) 0.83
2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. Int J Oncol (2010) 0.83
Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin. J Mass Spectrom (2010) 0.83
A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol (2002) 0.82
ERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female mice. Endocrinology (2013) 0.82
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol (2005) 0.82
1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate (2011) 0.81
Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089). Bone (2004) 0.81
Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications. Expert Opin Ther Pat (2010) 0.81
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. Pharm Res (2012) 0.80
A standards-based, peer-reviewed teaching award to enhance a medical school's teaching environment and inform the promotions process. Acad Med (2012) 0.80
Analysis of receptor phosphorylation. Methods Enzymol (2003) 0.80
Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos (2012) 0.79
Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3. Prostate (2003) 0.79
Alanine aminotransferase regulation by androgens in non-hepatic tissues. Pharm Res (2011) 0.79
1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate (2004) 0.78
Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. J Androl (2003) 0.78
Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs (2006) 0.78
Comparative study of nonlinear properties of EEG signals of normal persons and epileptic patients. Nonlinear Biomed Phys (2009) 0.77
The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Endocrinology (2014) 0.77
A role for site-specific phosphorylation of mouse progesterone receptor at serine 191 in vivo. Mol Endocrinol (2014) 0.75
Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer. Endocrinology (2012) 0.75